Yn dilyn cyhoeddiad NICE yr wythnos diwethaf ynglŷn â Trodelvy, beth yw'r diweddaraf o ran sicrhau ei fod ar gael i gleifion canser yng Nghymru ar y GIG?
Wedi'i ateb gan Y Gweinidog Iechyd a Gwasanaethau Cymdeithasol | Wedi'i ateb ar 01/08/2022
NICE published its final appraisal document recommending the use of Sacituzumab govitecan (Trodelvy®) for treating unresectable triple-negative advanced breast cancer after two or more previous therapies on 14 July. In accordance with the requirements of the New Treatment Fund, health boards must make Trodelvy® routinely available within two months.